<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399721</url>
  </required_header>
  <id_info>
    <org_study_id>PR008</org_study_id>
    <nct_id>NCT03399721</nct_id>
  </id_info>
  <brief_title>Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis</brief_title>
  <acronym>KOSNAR</acronym>
  <official_title>A Clinical Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chordate Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chordate Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, multicenter, double-blind, placebo-controlled trial in which&#xD;
      patients diagnosed with non-allergic rhinitis will be randomized to either intranasal&#xD;
      stimulation, or placebo treatment with the Chordate System at two occasions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, multi-center study in which patients diagnosed&#xD;
      with non-allergic rhinitis will receive intranasal stimulation with the Chordate System at&#xD;
      two occasions. Objectives are to evaluate the efficacy of the procedure in reducing disease&#xD;
      specific symptoms such as nasal congestion, rhinorrhea, nasal itching and sneezing, but also&#xD;
      to investigate the influence on quality of life, safety and tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal congestion</measure>
    <time_frame>3 month</time_frame>
    <description>The primary performance endpoint is the responder rate based on the change in the weekly median nasal congestion score (taken from Total Nasal Symptom Score (TNSS)) from baseline to the 3 month follow-up visit</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Nasal Congestion</condition>
  <condition>Non-allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Chordate S101 Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment With Device Chordate S101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chordate S101 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment With Device Chordate S101</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chordate S101</intervention_name>
    <description>Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time</description>
    <arm_group_label>Chordate S101 Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chordate S101 Placebo</intervention_name>
    <description>Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.</description>
    <arm_group_label>Chordate S101 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with persistent (&gt;12w) symptoms of non-allergic rhinitis dominated by nasal&#xD;
             congestion (± secretion) for an average of at least 1 h per day for at least 5 days&#xD;
             during a period of 14 days.&#xD;
&#xD;
          2. Having nasal congestion as major symptom, and a median nasal congestion score of at&#xD;
             least 2 (scale 0-3)&#xD;
&#xD;
          3. Male or female 18 - 65 years&#xD;
&#xD;
          4. Judged by the Investigator as suitable for participation in the study without safety&#xD;
             concerns based on medical history and physical examination.&#xD;
&#xD;
          5. Willing and able to provide written informed consent prior to participation in the&#xD;
             clinical investigation&#xD;
&#xD;
          6. Willing and able to comply with all study related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with Allergic rhinitis, demonstrated by either positive skin prick test,&#xD;
             Phadiatop or RAST during the last year.&#xD;
&#xD;
          2. Ongoing respiratory tract infection including nasal cavity at inclusion&#xD;
&#xD;
          3. Systemic steroid treatment less than 4 weeks before the inclusion in the study&#xD;
&#xD;
          4. Patients with a history of nasal surgery like: septoplasty, cosmetic surgery, conchal&#xD;
             surgery or any other nasal surgery except closed reposition for nasal fracture during&#xD;
             last year&#xD;
&#xD;
          5. History of frequent nose bleeds or a condition that increases the risk of excessive&#xD;
             bleeding&#xD;
&#xD;
          6. Pronounced anterior septal deviation or other significant nasal pathology at&#xD;
             endoscopic examination&#xD;
&#xD;
          7. Current malignancy of any kind&#xD;
&#xD;
          8. Known allergy to polyvinylchloride or medicinal liquid paraffin&#xD;
&#xD;
          9. Any disease, condition (medical or surgical) or drug or alcohol abuse which, in the&#xD;
             opinion of the investigator, might compromise the study results, or would place the&#xD;
             patient at increased risk.&#xD;
&#xD;
         10. Any implant with an electrical and/or neurostimulator device, including but not&#xD;
             limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain&#xD;
             stimulation, spinal stimulator, bone growth stimulator, or cochlear implant or any&#xD;
             other implant in the head-, and neck region.&#xD;
&#xD;
         11. Previous treated with radiation on the face, head or neck regions&#xD;
&#xD;
         12. Female patients who are pregnant or become pregnant at any time from inclusion of the&#xD;
             study until end of the 8 week follow-up visit&#xD;
&#xD;
         13. Received study drug in a clinical trial for an investigational drug within the&#xD;
             previous 30 days, or 5 half-lives, whichever is longer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charles University Faculty of Medicine in Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pardubice</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University Motol University Hospital</name>
      <address>
        <city>Prag</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aristotle University</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico A Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget University Hospital</name>
      <address>
        <city>Great Yarmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys Hospital, Greate Maze Pond</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

